Tresaderm (Canada)

(Neomycin (as Sulfate), Thiabendazole and Dexamethasone Dermatologic Solution)

Veterinary Use Only

Antibiotic

DIN 00270512

Product Description

Dermatologic Solution TRESADERM^® is a clear, light amber, slightly viscous liquid containing the following active ingredients per mL: 40 mg of thiabendazole, neomycin sulfate equivalent to 3.2 mg of neomycin base, and 1 mg of dexamethasone. The non-medicinal ingredients are: glycerin, propylene glycol, purified water, hypophosphorous acid, about 8.5% ethyl alcohol and about 0.5% benzyl alcohol.

Tresaderm Indications

Dermatologic Solution TRESADERM is indicated as an aid in the treatment of certain bacterial, mycotic, and inflammatory dermatoses as well as otitis externa in dogs and cats. It is also recommended for the treatment of inflammation associated with otoacariasis (infestation with Otodectes cynotis, ear mites). Both acute and chronic forms of these skin disorders respond to treatment with TRESADERM. Many forms of dermatosis are caused by bacteria, (chiefly Staphylococcus aureus, Proteus vulgaris and Pseudomonas aeruginosa). Moreover, these organisms often

act as opportunistic or concurrent pathogens that may complicate already established mycotic skin disorders, or otoacariasis caused by Otodectes cynotis. The principal etiologic agents of dermatomycoses in dogs and cats are species of the genera Microsporum and Trichophyton.

The efficacy of neomycin as an antibacterial agent, with activity against both Gram-negative and Gram-positive pathogens, is well documented. Detailed studies in various laboratories have verified the significant activity thiabendazole displays against the important dermatophytes. Dexamethasone, a synthetic adrenocorticoid steroid, inhibits the reaction of connective tissue to injury and suppresses the classic inflammatory manifestation of skin disease. The formulation of TRESADERM combines these several activities in a complementary form for control of the discomfort and direct treatment of dermatitis and otitis externa produced by the above-mentioned infectious agents.

Tresaderm Dosage And Administration

Prior to the administration of Dermatologic Solution TRESADERM remove the ceruminous, purulent or foreign material from the ear canal, as well as encrustations associated with dermatoses affecting other parts of the body. The design of the container nozzle safely allows partial insertion into the ear canal for ease of administration. The amount to apply and the frequency of treatment are dependent upon the severity of the condition. Five to 15 drops should be instilled in the ear two to three times daily. A second treatment, given two weeks after the first treatment, may be necessary to prevent the recurrence of the symptoms of otoacariasis. In treating dermatoses affecting other than the ear, the lesions should be well moistened (2 to 4 drops per square inch) with TRESADERM twice daily. TRESADERM is limited to 7 days maximum duration of administration.

Tresaderm Cautions

Intensive treatment requiring repeated application of Dermatologic Solution TRESADERM for extended periods may produce evidence of reversible skin irritation.

On rare occasions dogs may be sensitive to neomycin. Application of the drug will result in erythema of the treated area, which may last for 24 to 48 hours. Also evidence of transient discomfort has been noted in some dogs when the drug was applied to fissured or denuded areas. The expression of pain may last 2 to 5 minutes. If these conditions become clinically significant, use of the drug should be discontinued or frequency of application should be reduced.

Warnings

For topical use in animals only.

Avoid contact with skin or eyes.

Keep out of reach of children.

Storage

Store at 2-8°C.

Presentation

Dermatologic Solution TRESADERM is supplied in 7.5 mL and 15 mL applicator bottles.

Merial Canada Inc., 20000 Clark Graham, Baie d’ Urfé, QC H9X 4B6

TRESADERM is a registered trademark of Merial (a member of Boehringer Ingelheim group of companies), used under license.

Merial Limited, a company limited by shares registered in England and Wales (registered number 3332751) with a registered office at PO Box 327, Sandringham House, Sandringham Avenue, Harlow Business Park, Harlow, Essex CM19 5QA, England, and domesticated in Delaware, USA as Merial LLC, and having its place of business at 3239 Satellite Boulevard, Duluth, GA, U.S.A.

© 2017 Merial Canada Inc. (a member of Boehringer Ingelheim group of companies)

All Rights Reserved.

2050-2615-03

CPN: 1182069.3